-
New Treatment Option: Cosette Pharmaceuticals Receives FDA Approval for Evoxac Oral Solution
A New Milestone in Dry Mouth Treatment Patients suffering from the symptoms of Sjogren’s syndrome now have a new way to manage their condition. Cosette Pharmaceuticals, Inc. has officially announced that the U.S. Food and Drug Administration (FDA) has granted approval for Evoxac (cevimeline HCl) oral solution (15 mg/5 mL). This approval marks an important…
-
A Breakthrough in Sight: Amgen Announces Positive Phase 3 Results for Dazodalibep
NASDAQ: $AMGN Promising News for Sjögren’s Syndrome Patients There is a significant glimmer of hope for individuals living with moderate-to-severe systemic Sjögren’s syndrome. Amgen has officially announced positive topline results from their Phase 3 clinical trial evaluating dazodalibep, an investigational medicine designed to address the symptoms of this challenging autoimmune condition. Understanding the Clinical Trial…